Beam Therapeutics posts Q2 loss, doses first patient in BEAM-302 trial

August 4, 2026 7:00 AM

Beam Therapeutics (Nasdaq: BEAM) reported a net loss of $122.7 million, or $1.18 per share, for the second quarter of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found